These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35599363)

  • 21. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.
    Jeong J; Shin JW; Jung SW; Park EJ; Park NH
    Clin Mol Hepatol; 2022 Apr; 28(2):254-264. PubMed ID: 34959261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
    Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
    Viganò M; Loglio A; Grossi G; Lampertico P
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
    Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
    Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
    Brooks KM; Pinilla M; Stek AM; Shapiro DE; Barr E; Febo IL; Paul ME; Deville JG; George K; Knowles K; Rungruengthanakit K; Browning R; Chakhtoura N; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):343-350. PubMed ID: 35195573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    J Viral Hepat; 2021 Nov; 28(11):1570-1578. PubMed ID: 34435412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study.
    Han G; Zhou G; Sun T; Luo X; Xu J; Chen C; Xu W; Jiang S; Wang C
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10551-10558. PubMed ID: 36253882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis.
    Huang J; Cheng C; Li K; Zhu C; Liu Y
    Dig Dis Sci; 2024 Mar; 69(3):978-988. PubMed ID: 38341392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review.
    Zhao F; Lu H
    Biosci Trends; 2024 Jun; 18(2):141-152. PubMed ID: 38658364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    Liang LY; Yip TC; Lai JC; Lam AS; Tse YK; Hui VW; Chan HL; Wong VW; Wong GL
    J Med Virol; 2022 Sep; 94(9):4440-4448. PubMed ID: 35581529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B.
    Cao F; Fan T; Jiang X; Wang J; Liu Y; Zhu L; Xiong Y; Zhang S; Zhang Z; Pan Y; Li Y; Jiang C; Xia J; Yan X; Li J; Liu X; Zhu C; Huang R; Wu C
    Virol J; 2024 Sep; 21(1):234. PubMed ID: 39342240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers.
    Ji X; Li Y; Wang Z; Gao Y; Wang L
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):168-179. PubMed ID: 37953690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: a national cohort study.
    Ding Y; Cao L; Zhu L; Huang Y; Lin C; Wang Y; Liu Y; Sheng Q; Wang S; Fan J; Chen R; Gan W; Chen B; Pan CQ
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1377-1386. PubMed ID: 32852100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir alafenamide fumarate.
    Lee WA; Cheng AK
    Antivir Ther; 2022 Apr; 27(2):13596535211067600. PubMed ID: 35499175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.